Comparison of CDR3 amino acid sequence between primary and recurrent tumors in two representative cases.

Sakimura, Shotaro; Nagayama, Satoshi; Fukunaga, Mitsuko; Hu, Qingjiang; Kitagawa, Akihiro; Kobayashi, Yuta; Hasegawa, Takanori; Noda, Miwa; Kouyama, Yuta; Shimizu, Dai; Saito, Tomoko; Niida, Atsushi; Tsuruda, Yusuke; Otsu, Hajime; Matsumoto, Yoshihiro; Uchida, Hiroki; Masuda, Takaaki; Sugimachi, Keishi; Sasaki, Shin; Yamada, Kazutaka; Takahashi, Kazuki; Innan, Hideki; Suzuki, Yutaka; Nakamura, Hiromi; Totoki, Yasushi; Mizuno, Shinichi; Ohshima, Masanobu; Shibata, Tatsuhiro; Mimori, Koshi

doi:10.1371/journal.pgen.1009113.s002

pgen.1009113.s002.pdf (711.23 kB)

Comparison of CDR3 amino acid sequence between primary and recurrent tumors in two representative cases.

journal contribution

posted on 2021-01-21, 18:25 authored by Shotaro Sakimura, Satoshi Nagayama, Mitsuko Fukunaga, Qingjiang Hu, Akihiro Kitagawa, Yuta Kobayashi, Takanori Hasegawa, Miwa Noda, Yuta Kouyama, Dai Shimizu, Tomoko Saito, Atsushi Niida, Yusuke Tsuruda, Hajime Otsu, Yoshihiro Matsumoto, Hiroki Uchida, Takaaki Masuda, Keishi Sugimachi, Shin Sasaki, Kazutaka Yamada, Kazuki Takahashi, Hideki Innan, Yutaka Suzuki, Hiromi Nakamura, Yasushi Totoki, Shinichi Mizuno, Masanobu Ohshima, Tatsuhiro Shibata, Koshi Mimori

A) CRCR4; relapse-free survival (RFS) period (24.2 mo). Amino acid CATSMRTGDYNEQFF, TRBV15/TRBJ1-7 clone is identical between primary and recurrent tumors. B) CRCR9; RFS period (2.9 mo). Diversity is expanded and no identical clone was observed between primary and recurrent tumors.

(PDF)